A haploid genetic screen identifies heparan sulfate proteoglycans supporting Rift Valley fever virus infection

Journal of Virology

Volumn 90, Issue 3, 2016, Pages 1414-1423

  Riblett, Amber M ^a   Blomen, Vincent A ^b   Jae, Lucas T ^b   Altamura, Louis A ^c   Doms, Robert W ^d   Brummelkamp, Thijn R ^b,e   Wojcechowskyj, Jason A ^a,f,g  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e Cancer Genomics Center   (Netherlands)

^f GLADSTONE INSTITUTES   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEOHEPARAN SULFATE;

ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; GENE DISRUPTION; GENETIC SCREENING; GLYCOSYLATION; GOLGI COMPLEX; HAPLOIDY; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PATHOGENESIS; PHLEBOVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PTAR1 GENE; RIFT VALLEY FEVER VIRUS; START CODON; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS GENE; VIRUS RESISTANCE; VIRUS TITRATION; CELL LINE; GENETICS; METABOLISM; MUTAGENESIS; PHYSIOLOGY;

CELL LINE; GENETIC TESTING; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; MUTAGENESIS; RIFT VALLEY FEVER VIRUS; VIRUS ATTACHMENT;

EID: 84958074109     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02055-15     Document Type: Article

References (63)

1. Schmaljohn CS, Nichol ST. 2007. Bunyaviridae, p 1741-1789. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
2. Clements AC, Pfeiffer DU, Martin V, Otte MJ. 2007. A Rift Valley fever atlas for Africa. Prev Vet Med 82:72-82. http://dx.doi.org/10.1016/j.prevetmed.2007.05.006.
3. Madani T, Al-Mazrou YY, Al-Jeffri MH, Mishkhas A, Al-Rabeah AM, Turkistani AM, Al-Sayed MO, Abodahish A, Khan AS, Ksiazek TG, Shobokshi O. 2003. Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics. Clin Infect Dis 37:1084-1092. http://dx.doi.org/10.1086/378747.
4. Al-Hazmi M, Ayoola EA, Abdurahman M, Banzal S, Ashraf J, El-Bushra A, Hazmi A, Abdullah M, Abbo H, Elamin A, Al-Sammani E-T, Gadour M, Menon C, Hamza M, Rahim I, Hafez M, Jambavalikar M, Arishi H, Aqeel A. 2003. Epidemic Rift Valley fever in Saudi Arabia: a clinical study of severe illness in humans. Clin Infect Dis 36:245-252. http://dx.doi.org/10.1086/345671.
5. Daubney R, Hudson JR, Garnham PC. 1931. Enzootic hepatitis or Rift Valley fever. An undescribed virus disease of sheep cattle and man from East Africa. J Pathol Bacteriol 34:545-579.
6. Bird BH, Ksiazek TG, Nichol ST, MacLachlan NJ. 2009. Rift Valley fever virus. JAmVet Med Assoc 234:883-893. http://dx.doi.org/10.2460/javma.234.7.883.
7. Carette JE, Guimaraes CP, Varadarajan M, Park AS, Wuethrich I, Godarova A, Kotecki M, Cochran BH, Spooner E, Ploegh HL, Brummelkamp TR. 2009. Haploid genetic screens in human cells identify host factors used by pathogens. Science 326:1231-1235. http://dx.doi.org/10.1126/science.1178955.
8. Rosmarin DM, Carette JE, Olive AJ, Starnbach MN, Brummelkamp TR, Ploegh HL. 2012. Attachment of Chlamydia trachomatis L2 to host cells requires sulfation. Proc Natl Acad Sci U S A 109:10059-10064. http://dx.doi.org/10.1073/pnas.1120244109.
9. Carette JE, Guimaraes CP, Wuethrich I, Blomen VA, Sun C, Bell G, Yuan B, Muellner MK, Nijman M, Ploegh HL, Brummelkamp TR. 2011. Global gene disruption in human cells to assign genes to phenotypes. Nat Biotechnol 29:542-546. http://dx.doi.org/10.1038/nbt.1857.
10. Carette JE, Raaben M, Wong AC, Herbert AS, Obernosterer G, Mulherkar N, Kuehne AI, Kranzusch PJ, Griffin AM, Ruthel G, Dal Cin P, Dye JM, Whelan SP, Chandran K, Brummelkamp TR. 2011. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 477: 340-343. http://dx.doi.org/10.1038/nature10348.
11. Jae LT, Raaben M, Riemersma M, van Beusekom E, Blomen V, Velds A, Kerkhoven RM, Carette JE, Topaloglu H, Meinecke P, Wessels MW, Lefeber DJ, Whelan SP, van Bokhoven H, Brummelkamp TR. 2013. Deciphering the glycosylome of dystroglycanopathies using haploid screens for Lassa virus entry. Science 340:479-483. http://dx.doi.org/10.1126/science.1233675.
12. Jae LT, Raaben M, Herbert AS, Kuehne AI, Wirchnianski AS, Soh TK, Stubbs SH, Janssen H, Damme M, Saftig P, Whelan SP, Dye JM, Brummelkamp TR. 2014. Lassa virus entry requires a trigger-induced receptor switch. Science 344:1506-1510. http://dx.doi.org/10.1126/science.1252480.
13. de Boer SM, Kortekaas J, de Haan CAM, Moormann RJM, Bosch BJ. 2012. Heparan sulfate facilitates Rift Valley fever virus entry into the cell. J Virol 86:13767-13771. http://dx.doi.org/10.1128/JVI.01364-12.
14. Blomen VA, Májek P, Jae LT, Bigenzahn JW, Nieuwenhuis J, Staring J, Sacco R, van Diemen FR, Olk N, Stukalov A, Marceau C, Janssen H, Carette JE, Bennett KL, Colinge J, Superti-Furga G, Brummelkamp TR. 15 October 2015. Gene essentiality and synthetic lethality in haploid human cells. Science. http://dx.doi.org/10.1126/science.aac7557.
15. Ray N, Whidby J, Stewart S, Hooper JW, Bertolotti-Ciarlet A. 2010. Study of Andes virus entry and neutralization using a pseudovirion system. J Virol Methods 163:416-423. http://dx.doi.org/10.1016/j.jviromet.2009.11.004.
16. Higa MM, Petersen J, Hooper J, Doms RW. 2012. Efficient production of Hantaan and Puumala pseudovirions for viral tropism and neutralization studies. Virology 423:134-142. http://dx.doi.org/10.1016/j.virol.2011.08.012.
17. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25:402-408. http://dx.doi.org/10.1006/meth.2001.1262.
18. Cuellar K, Chuong H, Hubbell SM, Hinsdale ME. 2007. Biosynthesis of chondroitin and heparan sulfate in Chinese hamster ovary cells depends on xylosyltransferase II. J Biol Chem 282:5195-5200. http://dx.doi.org/10.1074/jbc. M611048200.
19. Pönighaus C, Ambrosius M, Casanova JC, Prante C, Kuhn J, Esko JD, Kleesiek K, Götting C. 2007. Human xylosyltransferase II is involved in the biosynthesis of the uniform tetrasaccharide linkage region in chondroitin sulfate and heparan sulfate proteoglycans. J Biol Chem 282:5201-5206. http://dx.doi.org/10.1074/jbc. M611665200.
20. Casanova JC, Kuhn J, Kleesiek K, Götting C. 2008. Heterologous expression and biochemical characterization of soluble human xylosyltransferase II. Biochem Biophys Res Commun 365:678-684. http://dx.doi.org/10.1016/j.bbrc.2007.10.206.
21. Okajima T, Yoshida K, Kondo T, Furukawa K. 1999. Human homolog of Caenorhabditis elegans sqv-3 gene is galactosyltransferase I involved in the biosynthesis of the glycosaminoglycan-protein linkage region of proteoglycans. J Biol Chem 274:22915-22918. http://dx.doi.org/10.1074/jbc.274.33.22915.
22. Kitagawa H, Tone Y, Tamura J, Neumann KW, Ogawa T, Oka S, Kawasaki T, Sugahara K. 1998. Molecular cloning and expression of glucuronyltransferase I involved in the biosynthesis of the glycosaminoglycan-protein linkage region of proteoglycans. J Biol Chem 273:6615-6618. http://dx.doi.org/10.1074/jbc.273.12.6615.
23. Bai X, Zhou D, Brown JR, Hennet T, Esko JD. 2001. Biosynthesis of the linkage region of glycosaminoglycans: cloning and activity of galactosyltransferase II, the sixth member of the beta 1, 3-galactosyltransferase family (beta 3GalT6). J Biol Chem 276:48189-48195.
24. Lind T, Tufaro F, McCormick C, Lindahl U, Lidholt K. 1998. The putative tumor suppressors EXT1 and EXT2 are glycosyltransferases required for the biosynthesis of heparan sulfate. J Biol Chem 273:26265-26268. http://dx.doi.org/10.1074/jbc.273.41.26265.
25. Aikawa J, Grobe K, Tsujimoto M, Esko JD. 2001. Multiple isozymes of heparan sulfate/heparin GlcNAc N-deacetylase/GlcN N-sulfotransferase. J Biol Chem 276:5876-5882. http://dx.doi.org/10.1074/jbc. M009606200.
26. Kamiyama S, Suda T, Ueda R, Suzuki M, Okubo R, Kikuchi N, Chiba Y, Goto S, Toyoda H, Saigo K, Watanabe M, Narimatsu H, Jigami Y, Nishihara S. 2003. Molecular cloning and identification of 3'-phosphoadenosine 5'-phosphosulfate transporter. J Biol Chem 278: 25958-25963. http://dx.doi.org/10.1074/jbc. M302439200.
27. Spicer AP, Kaback LA, Smith TJ, Seldin MF. 1998. Molecular cloning and characterization of the human and mouse UDP-glucose dehydrogenase genes. J Biol Chem 273:25117-25124. http://dx.doi.org/10.1074/jbc.273.39.25117.
28. Moriarity JL, Hurt KJ, Resnick AC, Storm PB, Laroy W, Schnaar RL, Snyder SH. 2002. UDP-glucuronate decarboxylase, a key enzyme in proteoglycan synthesis. J Biol Chem 277:16968-16975. http://dx.doi.org/10.1074/jbc. M109316200.
29. Ungar D, Oka T, Brittle EE, Vasile E, Lupashin V, Chatterton JE, Heuser JE, Krieger M, Waters MG. 2002. Characterization of a mammalian Golgi-localized protein complex, COG, that is required for normal Golgi morphology and function. J Cell Biol 157:405-415. http://dx.doi.org/10.1083/jcb.200202016.
30. Kingsley DM, Kozarsky KF, Segal M, Krieger M. 1986. Three types of low density lipoprotein receptor-deficient mutant have pleiotropic defects in the synthesis of N-linked, O-linked, and lipid-linked carbohydrate chains. J Cell Biol 102:1576-1585. http://dx.doi.org/10.1083/jcb.102.5.1576.
31. Eimer S, Gottschalk A, Hengartner M, Horvitz HR, Richmond J, Schafer WR, Bessereau J-L. 2007. Regulation of nicotinic receptor trafficking by the transmembrane Golgi protein UNC-50. EMBO J 26:4313-4323. http://dx.doi.org/10.1038/sj.emboj.7601858.
32. Charng WL, Yamamoto S, Jaiswal M, Bayat V, Xiong B, Zhang K, Sandoval H, David G, Gibbs S, Lu HC, Chen K, Giagtzoglou N, Bellen HJ. 2014. Drosophila Tempura, a novel protein prenyltransferase α subunit, regulates Notch signaling via Rab1 and Rab11. PLoS Biol 12: e1001777. http://dx.doi.org/10.1371/journal.pbio.1001777.
33. Gulberti S, Fournel-Gigleux S, Mulliert G, Aubry A, Netter P, Magdalou J, Ouzzine M. 2003. The functional glycosyltransferase signature sequence of the human beta 1, 3-glucuronosyltransferase is a XDD motif. J Biol Chem 278:32219-32226. http://dx.doi.org/10.1074/jbc. M207899200.
34. Byrnes AP, Griffin DE. 2000. Large-plaque mutants of Sindbis virus show reduced binding to heparan sulfate, heightened viremia, and slower clearance from the circulation. J Virol 74:644-651. http://dx.doi.org/10.1128/JVI.74.2.644-651.2000.
35. Sugahara Y, Matsumura T, Kono Y, Honda E, Kida H, Okazaki K. 1997. Adaptation of equine herpesvirus 1 to unnatural host led to mutation of the gC resulting in increased susceptibility of the virus to heparin. Arch Virol 142:1849-1856. http://dx.doi.org/10.1007/s007050050202.
36. Sa-Carvalho D, Rieder E, Baxt B, Rodarte R, Tanuri A, Mason PW. 1997. Tissue culture adaptation of foot-and-mouth disease virus selects viruses that bind to heparin and are attenuated in cattle. J Virol 71:5115-5123.
37. Schuksz M, Fuster MM, Brown JR, Crawford BE, Ditto DP, Lawrence R, Glass C, Wang L, Tor Y, Esko JD. 2008. Surfen, a small molecule antagonist of heparan sulfate. Proc Natl Acad Sci U S A 105:13075-13080. http://dx.doi.org/10.1073/pnas.0805862105.
38. Bente DA, Forrester NL, Watts DM, McAuley AJ, Whitehouse CA, Bray M. 2013. Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity. Antiviral Res 100: 159-189. http://dx.doi.org/10.1016/j.antiviral.2013.07.006.
39. Mir MA. 2010. Hantaviruses. Clin Lab Med 30:67-91. http://dx.doi.org/10.1016/j.cll.2010.01.004.
40. Banfield BW, Leduc Y, Esford L, Schubert K, Tufaro F. 1995. Sequential isolation of proteoglycan synthesis mutants by using herpes simplex virus as a selective agent: evidence for a proteoglycan-independent virus entry pathway. J Virol 69:3290-3298.
41. Bender FC, Whitbeck JC, Lou H, Gary H, Eisenberg RJ, Cohen GH. 2005. Herpes simplex virus glycoprotein B binds to cell surfaces independently of heparan sulfate and blocks virus entry. J Virol 79:11588-11597. http://dx.doi.org/10.1128/JVI.79.18.11588-11597.2005.
42. Lozach P-Y, Mancini R, Bitto D, Meier R, Oestereich L, Overby AK, Pettersson RF, Helenius A. 2010. Entry of bunyaviruses into mammalian cells. Cell Host Microbe 7:488-499. http://dx.doi.org/10.1016/j.chom.2010.05.007.
43. Filone CM, Heise M, Doms RW, Bertolotti-Ciarlet A. 2006. Development and characterization of a Rift Valley fever virus cell-cell fusion assay using alphavirus replicon vectors. Virology 356:155-164. http://dx.doi.org/10.1016/j.virol.2006.07.035.
44. Plassmeyer ML, Soldan SS, Stachelek KM, Martín-García J, González-Scarano F. 2005. California serogroup Gc (G1) glycoprotein is the principal determinant of pH-dependent cell fusion and entry. Virology 338: 121-132. http://dx.doi.org/10.1016/j.virol.2005.04.026.
45. Hofmann H, Li X, Zhang X, Liu W, Kühl A, Kaup F, Soldan SS, González-Scarano F, Weber F, He Y, Pöhlmann S. 2013. Severe fever with thrombocytopenia virus glycoproteins are targeted by neutralizing antibodies and can use DC-SIGN as a receptor for pH-dependent entry into human and animal cell lines. J Virol 87:4384-4394. http://dx.doi.org/10.1128/JVI.02628-12.
46. Tiwari V, O'Donnell C, Copeland RJ, Scarlett T, Liu J, Shukla D. 2007. Soluble 3-O-sulfated heparan sulfate can trigger herpes simplex virus type 1 entry into resistant Chinese hamster ovary (CHO-K1) cells. J Gen Virol 88:1075-1079. http://dx.doi.org/10.1099/vir.0.82476-0.
47. Choudhary S, Marquez M, Alencastro F, Spors F, Zhao Y, Tiwari V. 2011. Herpes simplex virus type-1 (HSV-1) entry into human mesenchymal stem cells is heavily dependent on heparan sulfate. J Biomed Biotechnol 2011:264350. http://dx.doi.org/10.1155/2011/264350.
48. Spear PG. 2004. Herpes simplex virus: receptors and ligands for cell entry. Cell Microbiol 6:401-410. http://dx.doi.org/10.1111/j.1462-5822.2004.00389.x.
49. Shukla D, Liu J, Blaiklock P, Shworak NW, Bai X, Esko JD, Cohen GH, Eisenberg RJ, Rosenberg RD, Spear PG. 1999. A novel role for 3-Osulfated heparan sulfate in herpes simplex virus 1 entry. Cell 99:13-22. http://dx.doi.org/10.1016/S0092-8674(00)80058-6.
50. Tsvitov M, Frampton AR, Shah WA, Wendell SK, Ozuer A, Kapacee Z, Goins WF, Cohen JB, Glorioso JC. 2007. Characterization of soluble glycoprotein D-mediated herpes simplex virus type 1 infection. Virology 360:477-491. http://dx.doi.org/10.1016/j.virol.2006.10.039.
51. Lozach P-Y, Kühbacher A, Meier R, Mancini R, Bitto D, Bouloy M, Helenius A. 2011. DC-SIGN as a receptor for phleboviruses. Cell Host Microbe 10:75-88. http://dx.doi.org/10.1016/j.chom.2011.06.007.
52. Hopkins KC, McLane LM, Maqbool T, Panda D, Gordesky-Gold B, Cherry S. 2013. A genome-wide RNAi screen reveals that mRNA decapping restricts bunyaviral replication by limiting the pools of dcp2-accessible targets for cap-snatching. Genes Dev 27:1511-1525. http://dx.doi.org/10.1101/gad.215384.113.
53. Esko JD, Kimata K, Lindahl U. 2009. Proteoglycans and sulfated glycosaminoglycans. In Varki A, Cummings RD, Esko JD, Freeze HH, Stanley S, Bertozzi CR, Hart GW, Etzler ME (ed), Essentials of glycobiology, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
54. Pietrantoni A, Fortuna C, Remoli ME, Ciufolini MG, Superti F. 2015. Bovine lactoferrin inhibits Toscana virus infection by binding to heparan sulphate. Viruses 7:480-495. http://dx.doi.org/10.3390/v7020480.
55. Ikegami T, Makino S. 2011. The pathogenesis of Rift Valley fever. Viruses 3:493-519. http://dx.doi.org/10.3390/v3050493.
56. Summerford C, Samulski RJ. 1998. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 72:1438-1445.
57. Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, Zhou X, Wilson JM. 2004. Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol 78:6381-6388. http://dx.doi.org/10.1128/JVI.78.12.6381-6388.2004.
58. Zhang F, Aguilera J, Beaudet JM, Xie Q, Lerch TF, Davulcu O, Colón W, Chapman MS, Linhardt RJ. 2013. Characterization of interactions between heparin/glycosaminoglycan and adeno-associated virus. Biochemistry 52:6275-6285. http://dx.doi.org/10.1021/bi4008676.
59. Parmley RT, Takagi M, Denys FR. 1984. Ultrastructural localization of glycosaminoglycans in human term placenta. Anat Rec 210:477-484. http://dx.doi.org/10.1002/ar.1092100308.
60. Gerdes GH. 2002. Rift Valley fever. Vet Clin North Am Food Anim Pract 18:549-555. http://dx.doi.org/10.1016/S0749-0720(02)00029-4.
61. Johnson KM, Kines RC, Roberts JN, Lowy DR, Schiller JT, Day PM. 2009. Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J Virol 83:2067-2074. http://dx.doi.org/10.1128/JVI.02190-08.
62. Park PJ, Antoine TE, Farooq A, Valyi-Nagy T, Shukla D. 2013. An investigative peptide-acyclovir combination to control herpes simplex virus type 1 ocular infection. Invest Ophthalmol Vis Sci 54:6373-6381. http://dx.doi.org/10.1167/iovs.13-12832.
63. Tiwari V, Liu J, Valyi-Nagy T, Shukla D. 2011. Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo. J Biol Chem 286:25406-25415. http://dx.doi.org/10.1074/jbc. M110.201103.